Cabozantinib shows promise as first line treatment for differentiated thyroid cancer
A kinase inhibitor called cabozantinib could be a viable therapy…
A kinase inhibitor called cabozantinib could be a viable therapy option for patients with metastatic, radioactive iodine-resistant thyroid cancer...